contributed by Dick Barker
Additional useful information in the Acoustic Neuroma Patient Archive:
Outcome Measure |
Pittsburgh GK | Virginia GK | Jefferson Univ GK | Jefferson Univ FSR | Johns Hopkins FSR | Stanford FSR | Staten Island Univ. Hosp. FSR | Loma Linda Proton |
Tumor Growth Control Rate | 97.1 +/- 1.9% |
94% | 98% | 97- 100% |
100% | 97% | 99% | 100% |
New-onset of transient or permanent facial weakness | 1.1 |
2.2% trans / 0-1.3% perm | 2% | 7% | 0% | 3% | 0-1% | 0% |
New-onset of transient or permanent facial numbness | 2.6 +/- 1.2% |
4% trans / 1.6% perm |
2% | 2% | 0% | 16% | 0-1% | 0% |
Hearing-level preservation | 71+/-4.7% | 58% | 73% | 77% | 69-94 | |||
Preservation of useful hearing2 | 73.5+/-5.9% | 33% (4 of 12) |
81% (17 of 21) | 31% (4 of 13) |
||||
Improved or resolved tinnitus | 11% (3 of 26) |
|||||||
Treatment Details |
Pittsburgh GK | Virginia GK | Jefferson Univ GK | Jefferson Univ FSR | Johns Hopkins FSR | Stanford FSR | Staten Island Univ. Hosp. FSR | Loma Linda Proton |
Number of patients included | 69 | 65 | 125 | 30 | ||||
Period of follow-up (years) | 2-7 | 1-10 | 2.3 | 2.2 | 1-5.7 | 0.5-4 | 3.5 yrs | 2.8 |
Tumor size (cm): mean diameter / range |
1.72 / 0.6-4 |
1.74 / 0.3-3.2 |
1.77 | 1.74 | 1.2 - 9.3cc3 | 2.0 / 0.7-4.2 |
2.6 cm | 2.0 cm |
Tumor dosage (Gy): mean / range |
26 / 22-36 |
34.3 / 17-53 |
? | 50 Gy in 35 fractions |
25-30 in 5 or 10 fractions |
21 Gy in 3 fractions |
20 Gy in 4 or 5 fractions |
54 Gy in 30 fractions |
Dosage to tumor margin (Gy): mean / range |
13 / 11-18 |
13.2 | 12 Gy |
Last Edited: Saturday, February 14, 2004